Citations (45)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jennifer N. Clements, Rachel Franks, Diana Isaacs, Kevin Malloy, Lisa T. Meade, Sara (Mandy) Reece, Debra J. Reid & Eileen D. Ward. (2023) Significant publications in diabetes pharmacotherapy and technology in 2020. Expert Review of Endocrinology & Metabolism 18:2, pages 131-142.
Read now
Read now
Steven G. Chrysant & George S. Chrysant. (2020) New and emerging cardiovascular and antihypertensive drugs. Expert Opinion on Drug Safety 19:10, pages 1315-1327.
Read now
Read now
Justyna Krzysztofik & Piotr Ponikowski. (2017) Current and emerging pharmacologic options for the management of patients with chronic and acute decompensated heart failure. Expert Review of Clinical Pharmacology 10:5, pages 517-534.
Read now
Read now
Articles from other publishers (42)
Ming-shuang Zhou, Shao-ying Zheng, Cheng Chen, Xue Li, Qin Zhang, Ya-jing Zhao & Wen Zhang. (2023) Gene expression analysis to identify mechanisms underlying improvement of myocardial fibrosis by finerenone in SHR. Biochemical Pharmacology, pages 115975.
Crossref
Crossref
Ruolin Lv, Lili Xu, Lin Che, Song Liu, Yangang Wang & Bingzi Dong. (2023) Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus. Frontiers in Endocrinology 14.
Crossref
Crossref
David S. H. Bell. (2022) Combine and Conquer: With Type 2 Diabetes Polypharmacy Is Essential Not Only to Achieve Glycemic Control but Also to Treat the Comorbidities and Stabilize or Slow the Advancement of Diabetic Nephropathy. Journal of Diabetes Research 2022, pages 1-8.
Crossref
Crossref
Sayoni Das, Krystyna Taylor, Simon Beaulah & Steve Gardner. (2022) Systematic indication extension for drugs using patient stratification insights generated by combinatorial analytics. Patterns 3:6, pages 100496.
Crossref
Crossref
Julie K. K. Vishram-Nielsen, Daniela Tomasoni, Finn Gustafsson & Marco Metra. (2022) Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction. Drugs 82:4, pages 375-405.
Crossref
Crossref
Xiao Lin, Muhammad Hasnain Ehsan Ullah, Xiong Wu, Feng Xu, Su-Kang Shan, Li-Min Lei, Ling-Qing Yuan & Jun Liu. (2022) Cerebro-Cardiovascular Risk, Target Organ Damage, and Treatment Outcomes in Primary Aldosteronism. Frontiers in Cardiovascular Medicine 8.
Crossref
Crossref
Oliver Schnell, Xavier Cos, Francesco Cosentino, Thomas Forst, Francesco Giorgino, Hiddo J. L. Heersprink, Mikhail Kosiborod, Christoph Wanner & Eberhard Standl. (2021) Report from the CVOT Summit 2020: new cardiovascular and renal outcomes. Cardiovascular Diabetology 20:1.
Crossref
Crossref
Srinivas Vinayak Shenoy, Shankar Prasad Nagaraju, Mohan Varadanayakanahalli Bhojaraja, Ravindra Attur Prabhu, Dharshan Rangaswamy & Indu Ramachandra Rao. (2021) Sodium‐glucose cotransporter‐2 inhibitors and non‐steroidal mineralocorticoid receptor antagonists: Ushering in a new era of nephroprotection beyond renin‐angiotensin system blockade. Nephrology 26:11, pages 858-871.
Crossref
Crossref
Daigoro Hirohama, Mitsuhiro Nishimoto, Nobuhiro Ayuzawa, Wakako Kawarazaki, Wataru FujiiShigeyoshi ObaShigeru ShibataTakeshi MarumoToshiro Fujita. (2021)
Activation of Rac1-Mineralocorticoid Receptor Pathway Contributes to Renal Injury in Salt-Loaded
db/db
Mice
. Hypertension 78:1, pages 82-93.
Crossref
Crossref
Omar Al Dhaybi & George L. Bakris. (2021) Mineralocorticoid Receptor Antagonists—Evidence for Kidney Protection, Trials With Novel Agents. Advances in Chronic Kidney Disease 28:4, pages 371-377.
Crossref
Crossref
Vishal Patel, Amit Joharapurkar & Mukul Jain. (2020) Role of mineralocorticoid receptor antagonists in kidney diseases. Drug Development Research 82:3, pages 341-363.
Crossref
Crossref
Qiannan Gao, Li Xu & Jun Cai. (2021) New drug targets for hypertension: A literature review. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1867:3, pages 166037.
Crossref
Crossref
Luis D’Marco, María Jesús Puchades, Lorena Gandía, Claudia Forquet, Elena Giménez-Civera, Nayara Panizo, Javier Reque, Isabel Juan-García, Valmore Bermúdez & José Luis Gorriz. (2021) Finerenone: A Potential Treatment for Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus. European Endocrinology 17:2, pages 84.
Crossref
Crossref
Michael R. Lattanzio & Matthew R. Weir. (2020) Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm. Kidney360 1:10, pages 1148-1156.
Crossref
Crossref
Vincenzo Marzolla, Alessandra Feraco, Stefania Gorini, Caterina Mammi, Carmen Marrese, Valentina Mularoni, Carla Boitani, Marc Lombès, Peter Kolkhof, Maria Rosa Ciriolo, Andrea Armani & Massimiliano Caprio. (2020) The novel non‐steroidal MR antagonist finerenone improves metabolic parameters in high‐fat diet‐fed mice and activates brown adipose tissue via AMPK‐ATGL pathway. The FASEB Journal 34:9, pages 12450-12465.
Crossref
Crossref
Liza Grosman-Rimon, Filio Billia, Evan Wright, Shemy Carasso, Gabby Elbaz-Greener, Erez Kachel, Vivek Rao & David Cherney. (2019) Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure. Heart Failure Reviews 25:5, pages 685-701.
Crossref
Crossref
Omar Al Dhaybi & George L. Bakris. (2020) Non‐steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease. Diabetes, Obesity and Metabolism 22:S1, pages 69-76.
Crossref
Crossref
John Funder. (2020) Primary aldosteronism: Treatment of the disease, and new therapeutic approaches. Best Practice & Research Clinical Endocrinology & Metabolism 34:2, pages 101368.
Crossref
Crossref
Daisuke Sueta, Eiichiro Yamamoto & Kenichi Tsujita. (2020) Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists. Current Hypertension Reports 22:3.
Crossref
Crossref
Stefania Gorini, Seung Kyum Kim, Marco Infante, Caterina Mammi, Sandro La Vignera, Andrea Fabbri, Iris Z. Jaffe & Massimiliano Caprio. (2019) Role of Aldosterone and Mineralocorticoid Receptor in Cardiovascular Aging. Frontiers in Endocrinology 10.
Crossref
Crossref
Jonatan Barrera-Chimal, Sophie Girerd & Frederic Jaisser. (2019) Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney International 96:2, pages 302-319.
Crossref
Crossref
Faiez Zannad, João Pedro Ferreira & Bertram Pitt. (2019) Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments. European Heart Journal Supplements 21:Supplement_A, pages A55-A60.
Crossref
Crossref
Steven M. Weldon & Nicholas F. Brown. 2019. Aldosterone. Aldosterone
211
239
.
Redi Llubani, Davor Vukadinović, Christian Werner, Nikolaus Marx, Stephen Zewinger & Michael Böhm. (2018) Hyperkalaemia in Heart Failure—Pathophysiology, Implications and Therapeutic Perspectives. Current Heart Failure Reports 15:6, pages 390-397.
Crossref
Crossref
Barry Greenberg. (2018) Mineralocorticoid receptor antagonists in heart failure: they work better when patients use them. European Journal of Heart Failure 20:9, pages 1335-1337.
Crossref
Crossref
Krister Bamberg, Ulrika Johansson, Karl Edman, Lena William-Olsson, Susanna Myhre, Anders Gunnarsson, Stefan Geschwindner, Anna Aagaard, Anna Björnson Granqvist, Frédéric Jaisser, Yufeng Huang, Kenneth L. Granberg, Rasmus Jansson-Löfmark & Judith Hartleib-Geschwindner. (2018) Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. PLOS ONE 13:2, pages e0193380.
Crossref
Crossref
Yu Zhao, Yunfei Li, Ling Tong, Xinying Liang, Han Zhang, Lan Li, Guanwei Fan & Yi Wang. (2018) Analysis of microRNA Expression Profiles Induced by Yiqifumai Injection in Rats with Chronic Heart Failure. Frontiers in Physiology 9.
Crossref
Crossref
Carlos M. Ferrario & Adam E. Mullick. (2017) Renin angiotensin aldosterone inhibition in the treatment of cardiovascular disease. Pharmacological Research 125, pages 57-71.
Crossref
Crossref
Farheen K. Dojki & George Bakris. (2017) Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease. Current Opinion in Nephrology and Hypertension 26:5, pages 368-374.
Crossref
Crossref
Peter Kolkhof & Lars Bärfacker. (2017) 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development. Journal of Endocrinology 234:1, pages T125-T140.
Crossref
Crossref
Li-Jing Sun, Yan-Ni Sun, Jian-Ping Shan & Geng-Ru Jiang. (2017) Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy. Journal of Diabetes Investigation 8:4, pages 609-618.
Crossref
Crossref
Bertram Pitt, Jo?o Pedro Ferreira & Faiez Zannad. (2017) Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives. European Heart Journal - Cardiovascular Pharmacotherapy 3:1, pages 48-57.
Crossref
Crossref
Anna Gromotowicz-Poplawska, Piotr Szoka, Patrycjusz Kolodziejczyk, Karol Kramkowski, Marzena Wojewodzka-Zelezniakowicz & Ewa Chabielska. (2016) New agents modulating the renin-angiotensin-aldosterone system—Will there be a new therapeutic option?. Experimental Biology and Medicine 241:17, pages 1888-1899.
Crossref
Crossref
Matthew D. Breyer & Katalin Susztak. (2016) Developing Treatments for Chronic Kidney Disease in the 21st Century. Seminars in Nephrology 36:6, pages 436-447.
Crossref
Crossref
Roland Heinig, Nina Kimmeskamp-Kirschbaum, Atef Halabi & Silvia Lentini. (2016) Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals With Renal Impairment. Clinical Pharmacology in Drug Development 5:6, pages 488-501.
Crossref
Crossref
S. M. Weldon, M. A. Cerny, K. Gueneva-Boucheva, D. Cogan, X. Guo, N. Moss, J.-H. Parmentier, J. R. Richman, G. A. Reinhart & N. F. Brown. (2016) Selectivity of BI 689648, a Novel, Highly Selective Aldosterone Synthase Inhibitor: Comparison with FAD286 and LCI699 in Nonhuman Primates. Journal of Pharmacology and Experimental Therapeutics 359:1, pages 142-150.
Crossref
Crossref
Pingping Yang, Tianlun Huang & Gaosi Xu. (2016) The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: Progress and challenges. Metabolism 65:9, pages 1342-1349.
Crossref
Crossref
Jehrod Brenneman, Jon Hill & Steve Pullen. (2016) Emerging therapeutics for the treatment of diabetic nephropathy. Bioorganic & Medicinal Chemistry Letters 26:18, pages 4394-4402.
Crossref
Crossref
Gerasimos Filippatos, Stefan D. Anker, Michael B?hm, Mihai Gheorghiade, Lars K?ber, Henry Krum, Aldo P. Maggioni, Piotr Ponikowski, Adriaan A. Voors, Faiez Zannad, So-Young Kim, Christina Nowack, Giovanni Palombo, Peter Kolkhof, Nina Kimmeskamp-Kirschbaum, Alexander Pieper & Bertram Pitt. (2016) A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal 37:27, pages 2105-2114.
Crossref
Crossref
Melvin D. Lobo, Paul A. Sobotka & Atul Pathak. (2016) Interventional procedures and future drug therapy for hypertension. European Heart Journal, pages ehw303.
Crossref
Crossref
Peter Kolkhof, Frederic Jaisser, So-Young Kim, Gerasimos Filippatos, Christina Nowack & Bertram Pitt. 2017. Heart Failure. Heart Failure
271
305
.
Kiyoshi Arai, Hiroyuki Tsuruoka & Tsuyoshi Homma. (2015) CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. European Journal of Pharmacology 769, pages 266-273.
Crossref
Crossref